C-CJQTMAIA
telomere targeting, immuno-oncology, small molecule
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-CJQT
C-CJQTC-CJQTtelomere targeting, immuno-oncology, small molecule
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The researchers propose conducting a multi-center, randomized, placebo-controlled study to investigate the potential role of etrasimod for the primary and secondary prevention of pouchitis among high-risk patients submitted to total proctocolectomy (TPC) with ileal-pouch anal anastomosis (IPAA) for medically refractory disease. The trial will be conducted in compliance with this protocol, Good Clinical Practice guidelines, and Institutional Review Board requirements.
THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to rapid telomere uncapping, genomic instability, and cell death. Cemiplimab is a programmed cell death protein 1 (PD-1) inhibitor recently approved as a first-line treatment for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. It is hypothesized that THIO administration prior to cemiplimab would restore tumor responses to immunotherapy in subjects who either developed resistance or relapsed after receiving first line treatment with an immune check point inhibitor.
The goal of this clinical trial is to learn whether the ColoMaia II software can help doctors find colon lesions during colonoscopy and whether it is safe to use in adults aged 40 to 80 years having screening, surveillance, or diagnostic colonoscopy. The main questions it aims to answer are whether the software increases the number of participants in whom at least one adenoma is found, and whether the software is safe to use during colonoscopy. Researchers will compare colonoscopy with ColoMaia II software assistance to standard colonoscopy without the software. Participants will be assigned to a colonoscopy with or without ColoMaia II software assistance, have a colonoscopy performed by a qualified physician, have tissue samples examined if needed, and allow study data and procedure videos to be collected and reviewed.
The purpose of this research study is to assess the safety and efficacy of fecal microbiota transplant (FMT) in the treatment of chronic pouchitis.
THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to rapid telomere uncapping, genomic instability, and cell death. Cemiplimab is a programmed cell death protein 1 (PD-1) inhibitor recently approved as a first-line treatment for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. It is hypothesized that THIO administration prior to cemiplimab would restore tumor responses to immunotherapy in subjects who either developed resistance or relapsed after receiving first line treatment with an immune check point inhibitor.
MAIA SHIRT – Thread & Supply Skip to content New! New! New Arrivals The Best Basics Shop All Shop All Tops Tops Tee Shop Tanks Button Ups Hoodies + Pullovers Sweaters + Cardigans Outerwear Outerwear Light Layers Jackets & Coats Vests Bottoms Bottoms Pants Joggers Skirts + Shorts Dresses Loungewear Loungewear Lounge Sets Lounge Tops Lounge Bottoms Recreation Recreation Recreation Tops Recreation Tees + Tanks Recreation Pullovers Recreation Bottoms Recreation Outerwear Recreation Dresses Recreation Sets Jumpsuits + Overalls Gift Card Sale Sale Shop All Sale Sale Tops Sale Tops Sale Tee … usiness days to process shipping When shipping to PO Boxes, additional fees may apply Shipping Status As soon as your order ships you will receive a shipping confirmation email that includes your tracking number If you do not receive an email confirmation - please contact us at [email protected] We do not ship on Saturday, Sundays or holidays If your order requires additional information to fully process we will be in touch by email Cancellation Poli cy Due to our fast
MAIA SHIRT – Thread & Supply Skip to content New! New! New Arrivals The Best Basics Shop All Shop All Tops Tops Tee Shop Tanks Button Ups Hoodies + Pullovers Sweaters + Cardigans Outerwear Outerwear Light Layers Jackets & Coats Vests Bottoms Bottoms Pants Joggers Skirts + Shorts Dresses Loungewear Loungewear Lounge Sets Lounge Tops Lounge Bottoms Recreation Recreation Recreation Tops Recreation Tees + Tanks Recreation Pullovers Recreation Bottoms Recreation Outerwear Recreation Dresses Recreation Sets Jumpsuits + Overalls Gift Card Sale Sale Shop All Sale Sale Tops Sale Tops Sale Tee … usiness days to process shipping When shipping to PO Boxes, additional fees may apply Shipping Status As soon as your order ships you will receive a shipping confirmation email that includes your tracking number If you do not receive an email confirmation - please contact us at [email protected] We do not ship on Saturday, Sundays or holidays If your order requires additional information to fully process we will be in touch by email Cancellation Poli cy Due to our fast
Business Sponsorship Motor Avenue Improvement Association Find us on Facebook! Mission Palms Community Weekend Membership Business Sponsorship Individual Membership Motor Ave Blog Farmers Market and Urban Garden Network Urban Garden Program Vendor Info Faith2Green Current Projects Street Improvements > Parklets Member-to-Member Program Parks/Development Expo Line Bike Infrastructure Events Local Businesses Business of the Month Newsletter Archive Ticket Trap and Traffic Previous Accomplishments E-Waste Recycling Community Valet City Charter Traffic Study PNC Elections PNC Elections 2
Maia Weekender – Herschel Supply Co. USA Skip to content Free Ground Shipping* Hassle-Free Returns Herschel Product Guarantee Free Ground Shipping* Enjoy free ground shipping on all orders +$75. Hassle-Free Returns Our 30-day return policy gives you time to make sure your purchase is right for the journeys ahead. Herschel Product Guarantee Buy with confidence. Warranty coverage across all product categories. Learn more Close Main Menu Herschel Supply Co. USA Search 0 Cart Bags Bags submenu Category Backpacks Totes Duffles Crossbodies Hip Packs & Slings Messengers Dry Bags Diaper Bags Gol … features for day-to-night use. Shop Foundation Company About Us Careers Credit Application Corporate Orders Dealer Portal Supply Chain Disclosure Company About Us Careers Credit Application Corporate Orders Dealer Portal Supply Chain Disclosure Support Customer Service Shipping Policy Returns FAQ Warranty Gift Cards Find a Store Support Customer Service Shipping Policy Returns FAQ Warranty Gift Cards Find a Store Legal Terms of Use Privacy Policy Website Accessibility Brand
MAIA Biotechnology, BeiGene announce clinical supply agreement - The Cancer Letter Skip to navigation Skip to content Search for: The Cancer Letter on Facebook The Cancer Letter on Twitter The Cancer Letter on LinkedIn The Cancer Letter The leading source for information on the issues that shape oncology since 1973 Home About Our Readers Our History Our Contributors Contact Us Store Current Issue Past Issues Podcast The Directors Events Job Board SUBSCRIBE Login SUBSCRIBE Login Search for: Home About Our Readers Our History Our Contributors Contact Us Store Current Issue Past Issues Podcast Th … nor for proton beam therapy Siteman receives renewal of five-year, $10.8M SPORE grant for leukemia research John Prensner awarded $250,000 grant to fight childhood brain tumors ACCC announces special grant to firefighter support network Report shows UPMC Hillman’s nearly $4B economic impact in Pennsylvania Clinical Roundup NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma Trastuzumab emtansine improves OS in HER2+ breast cancer, phase III … Applications are now being accepted for the Society for Immunotherapy of Cancer fellowship opportunities. This year, SITC is offering two fellowships totaling $150,000 in funding. March 20, 2026 Vol.52 No.11 Guest Editorial As more people are surviving cancer, we must continue funding bold science The cancer research community has a reason to celebrate. For the first time, 70% of people are living at least five years beyond their cancer diagnosis. And, as importantly, cancer … nor for proton beam therapy Siteman receives renewal of five-year, $10.8M SPORE grant for leukemia research John Prensner awarded $250,000 grant to fight childhood brain tumors ACCC announces special grant to firefighter support network Report shows UPMC Hillman’s nearly $4B economic impact in Pennsylvania Clinical Roundup NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma Trastuzumab emtansine improves OS in HER2+ breast cancer, phase III … ply agreement PREVIOUS ISSUE NEXT ISSUE Never miss an issue! Get alerts for our award-winning coverage in your inbox. Subscribe Login Username or Email Password Remember Me Forgot Password? Site license subscribers: Log in with your IP | Register a sponsored account
#scholarship #maia #scholarship #music #mentorship #sponsorship #mondaymotivation #education #musictech | Manon Dave | 31 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue … us. Today, Trusha and I are excited to share that we’re creating a full annual #scholarship in memory of #Maia . The Maia Saanvi #Scholarship for #Music will award one gifted girl a full scholarship to an academic institute to study a musical discipline of her choice. We’ll be sharing more information on how to apply, the partners and patrons of this scholarship soon, but in the meantime, please DM myself or Trusha if you’re interested in supporting through #mentorship or #sp … ls. Very inspiring to read 🎶 Like Reply 1 Reaction 2 Reactions Jason Grant 4y Report this comment Oh brother, I'm so sorry to read this and feel ashamed I didn't know about this earlier. The initiative is beyond inspirational and will make a massive impact I'm sure. Full support from me as always. May Maia's spirit forever bless the future musician. Like Reply 1 Reaction 2 Reactions Satish Chakravarthy 4y Report this comment Omg Manon ... I salute u for f
%PDF-1.4 %���� 1 0 obj > endobj 7 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 5 0 obj > endobj 6 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > endobj 13 0 obj > endobj 14 0 obj > endobj 15 0 obj > endobj 16 0 obj > endobj 17 0 obj > endobj 18 0 obj > endobj 19 0 obj > endobj 20 0 obj > endobj 21 0 obj > endobj 22 0 obj > endobj 23 0 obj > endobj 24 0 obj > endobj 25 0 obj > endobj 26 0 obj > endobj 27 0 obj > endobj 28 0 obj > endobj 29 0 obj > endobj 30 0 obj > endobj 31 0 obj > endobj 32 0 obj > endobj 33 0 obj > endobj
Maia Weekender – Herschel Supply Co. USA Skip to content Free Ground Shipping* Hassle-Free Returns Herschel Product Guarantee Free Ground Shipping* Enjoy free ground shipping on all orders +$75. Hassle-Free Returns Our 30-day return policy gives you time to make sure your purchase is right for the journeys ahead. Herschel Product Guarantee Buy with confidence. Warranty coverage across all product categories. Learn more Close Main Menu Herschel Supply Co. USA Search 0 Cart Bags Bags submenu Category Backpacks Totes Duffles Crossbodies Hip Packs & Slings Messengers Dry Bags Diaper Bags Gol … features for day-to-night use. Shop Foundation Company About Us Careers Credit Application Corporate Orders Dealer Portal Supply Chain Disclosure Company About Us Careers Credit Application Corporate Orders Dealer Portal Supply Chain Disclosure Support Customer Service Shipping Policy Returns FAQ Warranty Gift Cards Find a Store Support Customer Service Shipping Policy Returns FAQ Warranty Gift Cards Find a Store Legal Terms of Use Privacy Policy Website Accessibility Brand
Advertising Opportunities - MassAgent Skip to content About Board of Directors Meet Our Team Member Resources Agency Launch Program Ask A MAIA Specialist Marketing Resources Talent Solutions Information/Industry Links Agency Startup Toolkit Business Tools Five Star Agency Designation Business Consulting Education Calendar of Classes Licensing Designations and Certifications Live Webinars Employee Development Training at Your Site MA Licensing Info/Renewal/CE Lookup Scholarships, Training Funds, and Awards Cancellations/Education Policies MAIA Videos On Demand Education Partners Number One Agen
Careers | Maia Homes Skip to content Welcome to A Maximalist Menagerie - Now Accepting Bespoke Rug Orders. #1 Interior Designers' Choice for Maximalist Rugs. Be Our Trade Member. Complimentary Global Shipping and Easy Return. United States ‎(USD $)‎ { $store.xHeaderMenu.sectionId = "sections--22411198955763__header"; $store.xHeaderMenu.mobileHeaderLayout = "center-left"; $store.xHeaderMenu.initSticky($el, "reduce-logo-size"); }' :class="($store.xMiniCart.open || $store.xHeaderMenu.show) && 'z-[60]'" @click.away="$store.xHeaderMenu.openHamburgerMenu = false;" > { $store.xMobileNav … of a dynamic team, we invite you to join us in shaping the future of our brand. Apply now to embark on an exciting journey with us! Position: Rug Textile Designer (Full-time, Remote) We're seeking a talented Rug Textile Designer to join our team. As a remote member of our creative force, you'll play a pivotal role in shaping the aesthetic appeal of our rug collections. Responsibilities: Develop and implement innovative rug designs using industry-standard software such as Gala … commercially viable rug designs. Thorough understanding of color theory and its application in design. Proven ability to thrive in a fast-paced environment and deliver results under tight deadlines. Preference will be given to candidates with experience in design research and a keen awareness of market trends. How to Apply: Interested candidates are invited to apply by sending their resume along with an exceptional design portfolio showcasing prior work and technical skills t … work and technical skills to [email protected] with the subject line: Round 1 Application - Position - First Name, Last Name. Position: Copywriter (Full-time, Remote) We're seeking a talented Copywriter to join our team and help us weave compelling narratives that resonate with our audience. Responsibilities: Collaborate with the marketing and creative teams to develop engaging and impactful copy for various platforms, including website content, product descriptions, social … dlines. Experience working in a remote or virtual environment is a plus. How to Apply: Interested candidates are invited to apply by sending their resume along with relevant portfolio showcasing prior work and technical skills to [email protected] with the subject line: Round 1 Application - Position - First Name, Last Name. Position: Sales Deve
EX-10.1 3 maia-ex101_313.htm EX-10.1 maia-ex101_313.htm Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL SUPPLY AND NON-EXCLUSIVE LICENSE AGREEMENT This Supply and Non-Exclusive License Agreement (“Agreement” ), made as of February 1, 2021 (the “Effective Date” ), is by and between Regeneron Pharmaceuticals, Inc. (“Regeneron” ), having a place of business at 777 Old Saw … be contained in) the chemistry, manufacturing and controls section of an IND or application for Regulatory Approval for such Product in the United States, or the equivalent section of corresponding regulatory filings made outside the United States. For the avoidance of doubt, the information described in the preceding sentence is CMC information regardless of what document it is contained in or the form in which it is disclosed. 1.8. “ Combination ” means the use … y right, possession by a Party or its Affiliates (whether by ownership, license grant or other means) of the legal right to grant the right to access or use, or to grant a license or a sublicense to, such Patent, data or other intellectual property right as provided for herein without violating the terms of any agreement or other arrangement between such Party (or any of its Affiliates) and any Third Party. 1.14. “ Delivery ” has the meaning set forth in Section 9 … enerated in the performance of this Agreement. 1.27. “IND” means an application filed with a Regulatory Authority for authorization to commence clinical trials, including (a) an Investigational New Drug Application as defined in the FFDCA or any successor application or procedure filed with the FDA, (b) any equivalent of a United States IND in other countries or regulatory jurisdictions, (e.g., clinical trial application (CTA)), and (c) all supplements, amendments … to any of the foregoing, in any part of the world, together with the rights to apply for the registration of any such right. For the avoidance of doubt, Intellectual Property for purposes of this Agreement expressly excludes all Trademark rights. 1.29. “IRB/EC” has the meaning set forth in Section 4.1. 1.30. “Joint Patent Appli
%PDF-1.7 %���� 1 0 obj >/Metadata 1536 0 R/ViewerPreferences 1537 0 R>> endobj 2 0 obj > endobj 3 0 obj >/Pattern >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 88 0 R 89 0 R 90 0 R] /MediaBox[ 0 0 2592 1512] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��}[�$�����zl�R�N. ���ja��SZ��` ��m�g�Z�V����e\H��Uu�h��>Ɋ�$�A$������y�����o�:�租,��,��^��vI �S���ͧ���/�>��ߝ�ở>�D ���J�% ��ŧ����O���_�d��b�f6�Q����b��� �cvʨp �'٣vrC9�� ~�� ��[�|Οf9�Pq���}}O�����b9���� wx���� �᧧w�LK��6�|��R���cZɗ�~� �bQ�$��h��(I�Ŏ��I���� N�D& u� 'I"��ώ��$QV
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas :: MAIA Biotechnology, Inc. (MAIA) About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu x LinkedIn Press Releases Investors Investors Overview News & Events Press Releases IR Calendar Email Alerts Company Info Management Team Analyst Coverage Presentations Contacts FAQ Stock Data Quote Ch … rs a highly valuable incentive for MAIA. Upon FDA approval of a future new drug application in PDHGG, MAIA would be eligible to receive a priority review voucher that can be redeemed or sold as an asset at a very high valuation.” Rare pediatric disease priority review vouchers ( PRVs) can be redeemed by drug developers for FDA priority review of a different product or transferred or sold to another sponsor. Since 2015, FDA priority review vouchers have sold as assets at an av
Careers | Maia Homes Skip to content Welcome to A Maximalist Menagerie - Now Accepting Bespoke Rug Orders. #1 Interior Designers' Choice for Maximalist Rugs. Be Our Trade Member. Complimentary Global Shipping and Easy Return. United States ‎(USD $)‎ { $store.xHeaderMenu.sectionId = "sections--22411198955763__header"; $store.xHeaderMenu.mobileHeaderLayout = "center-left"; $store.xHeaderMenu.initSticky($el, "reduce-logo-size"); }' :class="($store.xMiniCart.open || $store.xHeaderMenu.show) && 'z-[60]'" @click.away="$store.xHeaderMenu.openHamburgerMenu = false;" > { $store.xMobileNav … of a dynamic team, we invite you to join us in shaping the future of our brand. Apply now to embark on an exciting journey with us! Position: Rug Textile Designer (Full-time, Remote) We're seeking a talented Rug Textile Designer to join our team. As a remote member of our creative force, you'll play a pivotal role in shaping the aesthetic appeal of our rug collections. Responsibilities: Develop and implement innovative rug designs using industry-standard software such as Gala … commercially viable rug designs. Thorough understanding of color theory and its application in design. Proven ability to thrive in a fast-paced environment and deliver results under tight deadlines. Preference will be given to candidates with experience in design research and a keen awareness of market trends. How to Apply: Interested candidates are invited to apply by sending their resume along with an exceptional design portfolio showcasing prior work and technical skills t … work and technical skills to [email protected] with the subject line: Round 1 Application - Position - First Name, Last Name. Position: Copywriter (Full-time, Remote) We're seeking a talented Copywriter to join our team and help us weave compelling narratives that resonate with our audience. Responsibilities: Collaborate with the marketing and creative teams to develop engaging and impactful copy for various platforms, including website content, product descriptions, social … dlines. Experience working in a remote or virtual environment is a plus. How to Apply: Interested candidates are invited to apply by sending their resume along with relevant portfolio showcasing prior work and technical skills to [email protected] with the subject line: Round 1 Application - Position - First Name, Last Name. Position: Sales Deve
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies :: MAIA Biotechnology, Inc. (MAIA) About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu x LinkedIn Press Releases Investors Investors Overview News & Events Press Releases IR Calendar Email Alerts Company Info Management Team Analyst Coverage Presentations Contacts FAQ Stock Data Quote Charts Historical
and tags, as close as possible to the opening tag. Creation Date: 08/25/2016 --> contact us Menu × about Who we are Success stories Staff Board of Directors & Committee Members site selection grow here Relocate Here Expand Here Find a Site investors Major Investors Investor Directory Become an Investor Strategic Partners Investor Directory --> Payment Portal Resources incentives Federal Incentives New York State Incentives Orange County Incentives Utility Incentives demographics statistical data workforce infrastructure Target Industries Our Cities quality of life industry experts direct
Maia & Mou Skip to content About Contact Shop Shop Tops Bottoms Dresses Kids Footwear Infant Outfits & Shoes Hats Adults Overalls & Shortalls Markets Log in https://www.facebook.com/profile.php?id=61573611484602 https://www.instagram.com/maiaandmou/ About Contact Shop Tops Bottoms Dresses Kids Footwear Infant Outfits & Shoes Hats Adults Overalls & Shortalls Markets Search Log in Cart Item added to your cart View cart Check out Continue shopping $10 FLAT RATE SHIPPING/$15 EXPRESS. AFTERPAY AVAILABLE EOFY SALE 30% off your fave rugby sweaters, trackies, overalls & long sleeve
Jobs × 🎁 You have got a free gift! Add your free gift to the cart Skip to content - reviews Open navigation menu Open search Shop New Singles Bundles By routine step Cleanse Exfoliate Mask Tone Treat Moisturise Protect By skin type Blemished skin Combination skin Dry skin Oily skin Normal skin By body part Face Body Accessories Bestsellers Knowledge Ingredients Guide Blog About Mission Sustainability Production Ingredients Story Press Diagnostic → Bestsellers Viva Maia EN Language English Deutsch Open search Open account page Open cart 0 Shop Knowledge About Diagnostic → Bestsellers Eng … ll backgrounds, identities, and experiences. If you need any adjustments to the application process, just let us know. Job openings We currently have no open positions, but we are always interested in connecting with talented individuals who share our passion for blending tradition with innovation. Please feel free to submit your resume to [email protected] , and we'll keep it on file for future opportunities. Become part of our community, secure exclusive benefits, and st
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Careers | Maia Homes Skip to content Welcome to A Maximalist Menagerie - Now Accepting Bespoke Rug Orders. #1 Interior Designers' Choice for Maximalist Rugs. Be Our Trade Member. Complimentary Global Shipping and Easy Return. United States ‎(USD $)‎ { $store.xHeaderMenu.sectionId = "sections--22411198955763__header"; $store.xHeaderMenu.mobileHeaderLayout = "center-left"; $store.xHeaderMenu.initSticky($el, "reduce-logo-size"); }' :class="($store.xMiniCart.open || $store.xHeaderMenu.show) && 'z-[60]'" @click.away="$store.xHeaderMenu.openHamburgerMenu = false;" > { $store.xMobileNav … of a dynamic team, we invite you to join us in shaping the future of our brand. Apply now to embark on an exciting journey with us! Position: Rug Textile Designer (Full-time, Remote) We're seeking a talented Rug Textile Designer to join our team. As a remote member of our creative force, you'll play a pivotal role in shaping the aesthetic appeal of our rug collections. Responsibilities: Develop and implement innovative rug designs using industry-standard software such as Gala … commercially viable rug designs. Thorough understanding of color theory and its application in design. Proven ability to thrive in a fast-paced environment and deliver results under tight deadlines. Preference will be given to candidates with experience in design research and a keen awareness of market trends. How to Apply: Interested candidates are invited to apply by sending their resume along with an exceptional design portfolio showcasing prior work and technical skills t … work and technical skills to [email protected] with the subject line: Round 1 Application - Position - First Name, Last Name. Position: Copywriter (Full-time, Remote) We're seeking a talented Copywriter to join our team and help us weave compelling narratives that resonate with our audience. Responsibilities: Collaborate with the marketing and creative teams to develop engaging and impactful copy for various platforms, including website content, product descriptions, social … dlines. Experience working in a remote or virtual environment is a plus. How to Apply: Interested candidates are invited to apply by sending their resume along with relevant portfolio showcasing prior work and technical skills to [email protected] with the subject line: Round 1 Application - Position - First Name, Last Name. Position: Sales Deve
MAIA Property and Casualty Licensing Course - Big I Michigan Skip to main content (Press Enter). Sign in Skip auxiliary navigation (Press Enter). Contact Us Code of Conduct Skip main navigation (Press Enter). Toggle navigation About Us About Us Big I Michigan Leadership Big I Michigan Committees NextGen Leaders of Michigan NextGen Upcoming Events The Big I Michigan Team Big I Michigan Award Winners Membership Join or Renew Member Benefits Overview Supporting Partners Find a Member MI Future Foundation Genesee County Agents Bay Area Insurance Agents Association Oakland County Agent … gan Leadership Big I Michigan Committees The Big I Michigan Team Big I Michigan Award Winners Membership Join or Renew Member Benefits Overview Supporting Partners Find a Member MI Future Foundation Genesee County Agents Bay Area Insurance Agents Association Oakland County Agents West Michigan Golf Outing Continuing Education Calendar of Programs & Events Education Programs Events Flagship Events Additional Big I Michigan Events Products/Services E&O Insurance Cyber Insurance
Careers at Maia Farms | Grow the Future with Us Skip to content { $sectionApi.update({ waitForIdle: true, batch: true, cachePolicy: 'network-only' }) }, 500); } $watch('$dialog.isOpen', async (isDrawerOpen) => { if (isDrawerOpen) { await $dialog.waitForAnimations() $sectionApi.update({ waitForIdle: true, cachePolicy: 'network-only' }) } }) " x-cart-api-section > Cart Error loading cart Refresh Products Overview FORM FLOUR Applications Purchase Sample Wholesale Learn Nourish Life Case studies Recipes Press FAQ About About Maia Team Careers Contact Instagram, Opens in new tab YouTube, Opens in n … ercialization. Work closely with Maia's Innovation team to address formulation, application, and technical questions. Help customers understand how Maia ingredients can improve nutrition, functionality, yield, clean-label claims, and cost-in-use. Act as the primary point of contact throughout the evaluation process. Accelerate Pipeline Conversion Keep projects moving by maintaining regular customer communication and follow-up. Identify and remove barriers that slow customer a … duce the time required to move customers from product development to commercial proposal and purchase order. Pipeline Management & Market Development Maintain accurate opportunity tracking, forecasting, and customer records within Copper CRM. Monitor pipeline health and identify opportunities to improve qualification and conversion rates. Represent Maia Farms at trade shows, customer meetings, and industry events. Gather market intelligence and customer feedback to support fu … with our values, and we encourage qualified candidates from all backgrounds to apply. [email protected] of of Headquarters 120 - 126 W 3rd Ave, Vancouver, BC Canada V5Y 1E9 [email protected] Company About Case Studies Press Support Contact FAQ Careers Newsletter Sign up to hear about our product innovations, and insights into the world of climate-smart food manufacturing. Email Join This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service ap … cessing your order... Please be patient... Something went wrong... Try again Ok Submit your order ✕ First Name* Email/Phone number This field is required invalid_email Apply Discount code isn't valid Discount code isn’t valid for the items in your cart Subtotal Discount TOTAL Continue shopping Submit Inquiry €eopmarker Please enter the sit
Licensing - MassAgent Skip to content About Board of Directors Meet Our Team Member Resources Agency Launch Program Ask A MAIA Specialist Marketing Resources Talent Solutions Information/Industry Links Agency Startup Toolkit Business Tools Five Star Agency Designation Business Consulting Education Calendar of Classes Licensing Designations and Certifications Live Webinars Employee Development Training at Your Site MA Licensing Info/Renewal/CE Lookup Scholarships, Training Funds, and Awards Cancellations/Education Policies MAIA Videos On Demand Education Partners Number One Agency Coverage for … 62L. (a) A person applying for a resident insurance producer license shall make application to the commissioner on the uniform application and declare under penalty of refusal, suspension or revocation of the license that the statements made in the application are true, correct and complete to the best of the individual's knowledge and belief. Before approving the application, the commissioner shall find that the individual:— (1) is at least 18 years of age; (2) has not commi
Jobs × 🎁 You have got a free gift! Add your free gift to the cart Skip to content - reviews Open navigation menu Open search Shop New Singles Bundles By routine step Cleanse Exfoliate Mask Tone Treat Moisturise Protect By skin type Blemished skin Combination skin Dry skin Oily skin Normal skin By body part Face Body Accessories Bestsellers Knowledge Ingredients Guide Blog About Mission Sustainability Production Ingredients Story Press Diagnostic → Bestsellers Viva Maia EN Language English Deutsch Open search Open account page Open cart 0 Shop Knowledge About Diagnostic → Bestsellers Eng … ll backgrounds, identities, and experiences. If you need any adjustments to the application process, just let us know. Job openings We currently have no open positions, but we are always interested in connecting with talented individuals who share our passion for blending tradition with innovation. Please feel free to submit your resume to [email protected] , and we'll keep it on file for future opportunities. Become part of our community, secure exclusive benefits, and st
Careers | MAIA Analytics Solutions Use cases About us Log in Book a demo Solutions Use cases About us Log in Book a demo Shape the future of geospatial intelligence Open roles Senior Data Engineer San Francisco, CA (Hybrid) Backend Engineer San Francisco, CA (Hybrid) The fastest way to get real answers from the physical world. Book a demo Product Solutions Use cases Company About us Careers Data Trust Privacy Terms Contact [email protected] Follow us LinkedIn @maia_analytics Copyright © 2025 MAIA Analytics, Inc. All rights reserved.
MAIA Biotechnology, Inc. Announces Research Collaboration with Nationwide Children’s Hospital to Evaluate THIO in Combination with Standard-of-Care Cancer Therapies :: MAIA Biotechnology, Inc. (MAIA) About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu x LinkedIn Press Releases Investors Investors Overview News & Events Press Releases IR Calendar Email Alerts Company Info Management Team Analyst Coverage Pres
Small Agency Conference 2026 Education Calendar - MAIA IIABA National About Us About MAIA MAIA Staff Committees Board of Directors Awards MAIA Office Location & Hours Find an Agent Membership Directory Search for an Agent Login IndependentAgent.com Close IIABA National menu About the Independent Insurance Agents & Brokers of America Find an Agent Find Your State MAIA logo Education & Events Back Education & Events Education Events Education Calendar Find available courses and register AILP Distinguished, advanced-level designation designed for insurance professionals Other … o if a disaster hits, as well as information on the Bobby Salmon Big "I" Relief Fund Internship Guide A step-by-step guide to hiring, employing and evaluating interns Invest This program is dedicated to improving insurance literacy and attracting new talent to the industry Diversity Find resources and get involved in programs designed to bring diverse talent into the independent agency system Why Choose an Independent Agent Some people think it doesn't really matter where the
MaiaSpace Careers Home Skip to content MaiaSpace Homepage MaiaSpace Homepage MaiaSpace Homepage MaiaSpace Homepage MaiaSpace Homepage MaiaSpace Homepage MaiaSpace Homepage MaiaSpace Homepage JOIN THE MISSION Open Positions 🚀 Are you ready to take part in shaping Europe’s future access to space? As, at MaiaSpace, we accelerate our development with our reusable mini-launcher, we are thrilled to announce exciting opportunities for talented individuals like you. 🫵 If you are ready to roll up your sleeves and dive into the challenges required to achieve our roadmap through design, prototype manuf
%PDF-1.7 %���� 1 0 obj >/Metadata 367 0 R/ViewerPreferences 368 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]ms�8�����~��,�Ɨ����lf*WI]v'�WW�� [��[K�It ���W����*y��m���$��T�yVIj5�O�@2���Y�_���a�2)L�EЂ�l����fV�{|�Jf"O����L���j��t�v�A �U�XsN�*�f h� �,��J?B7Wkxq��y* VEâe��\��g ��&�8+`��=��tL8^u��d� ���v�@*N;��n?�`2F���t9���̼�`�� ��ԋы E/%� �k�S�OH����L 0H����E2���C oM�l�50�y��dp���r��/���b��Wp?�%7�|��>_L �aG���G:2��D@�q�
Skrey - Tech Show Madrid NOVEMBER 4 -5, 2026 IFEMA MADRID, HALLS 3 - 5 Linkedin Twitter MENU Home List of exhibitors Program Cloud & AI Infrastructure Cyber Security World Big Data & AI World Data Centre World E-SHOW HR & Learning Technologies Complete Program Speakers Why exhibit? Why visit? News CO-LOCATED SHOWS Cloud & AI Infrastructure Cyber Security World Big Data & AI World Data Centre World Technology for Marketing --> E-Show HR Technologies Learning Technologies Exhibitors Skrey Booth: S07 Summary Address Rua Simão Bolívar 239, 5ºAndar, Room 3/4 Maia MAIA 4470-151 Portugal Webs … Message * Contact Message * Contact Message Please enter the code shown above * Submit Contact Request Loading SEE ALL EXHIBITORS NTT Global Data Centers Evernex Partners Institutional Support Institutional Support Institutional Support Institutional Support Event Partner Event Partner Strategic Partner Event Partner Event Partner Event Partner Event Partner Event Partner Event Partner
Join MAIA Digital | Careers Skip to content Services Company Page Management LinkedIn Ads Personalized Trainings Thought Leadership Profile Optimization Employer Branding Resources Podcasts Blog Press Hub Tutorial Hub Linktionary Profile Score About Us Our Story Graphic Studio Social Impact Careers Services Company Page Management LinkedIn Ads Personalized Trainings Thought Leadership Profile Optimization Employer Branding Resources Podcasts Blog Press Hub Tutorial Hub Linktionary Profile Score About Us Our Story Graphic Studio Social Impact Careers Services Company Page Management LinkedIn Ad … ards Unmatched Expertise, Unparalleled Results MAIA receives its first industry award, validating our commitment to excellence. Early 2022 Accordion Title Accordion Content New Services & Partnerships Broadening Our Horizon New services rolled out and strategic partnerships forged to offer you an even broader spectrum of LinkedIn solutions. Present Day Accordion Title Accordion Content Your Success, Our Journey Continuity is the key The team is growing, the expertise is sharp … e're always on the lookout for talented individuals. Please check back later or submit your resume to be considered for future opportunities Contact Us Full Name Email Address Phone Number How'd you find us? LinkedIn Lecture or Workshop Podcast Friends Google Facebook ChatGPT Claude Gemini Other Message I agree to receive reminders, useful content and marketing materials. Send [email protected] +972-52-333-9400 REGUS, Sapir 7, Herzliya Our Services Company Page Managemen
Sponsor and Exhibitor Opportunities - University of Southern Indiana --> Contact USI Your Name Name is required Your Email Email must be valid Your Question/Comment Question/Comment is required Your Comment Clear Send Skip to content Sponsor and Exhibitor... Back Kinney College of Nursing and Health Professions Navigation Kinney College of Nursing and... Center for Health Professions... Conferences and Workshops Sponsor and Exhibitor... Kinney College of Nursing and... Kinney College of Nursing and... About the College Kinney College of Nursing and... About the College Handbook for Kinney Coll … inney College of Nursing and... Bronstein Center for Healthy Aging... Bronstein Award Recipients Kinney College of Nursing and... Bronstein Center for Healthy Aging... Dementia Education Kinney College of Nursing and... Bronstein Center for Healthy Aging... Annual Report Kinney College of Nursing and... Bronstein Center for Healthy Aging... Annual Report 2022-2023 Annual Report Kinney College of Nursing and... Bronstein Center for Healthy Aging... Annual Report 2023-2024 Annu … ollege of Nursing and... Food and Nutrition Alumni Spotlight Alumni Spotlight - Grant Buckley Kinney College of Nursing and... Food and Nutrition Alumni Spotlight Alumni Spotlight - Sylvia Crowder Kinney College of Nursing and... Food and Nutrition Alumni Spotlight Alumni Spotlight - Allie Ennis Kinney College of Nursing and... Food and Nutrition Alumni Spotlight Alumni Spotlight - Molly Gilles Kinney College of Nursing and... Food and Nutrition Alumni Spotlight Alumni Spotli … ing and... Health Administration and... Health Administration and... Graduation Application and... Kinney College of Nursing and... Health Administration and... Health Administration and... General Information Kinney College of Nursing and... Health Administration and... Gerontology at USI Kinney College of Nursing and... Health Administration and... Gerontology at USI Undergraduate Curriculum Kinney College of Nursing and... Health Administration and... Gerontology at USI Un … ate Nursing Program Graduate Nursing Handbook Appendix and Forms MSN Appendix C Application For MSN... Kinney College of Nursing and... Graduate Nursing Program Graduate Nursing Handbook Appendix and Forms MSN Professional Agreement Form... Kinney College of Nursing and... Graduate Nursing Program Graduate Nursing Handbook Appendix and Forms MSN
Privacy Policy - Maia Biotechnology About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu X LinkedIn Privacy Policy Introduction MAIA Biotechnology, Inc. (thereafter MAIA) operate a website designed to provide you with information and services, including but not limited to our drug development, and corporate information. Whether you are a patient, healthcare provider, investor, or job applicant, respect for the pr … identifiable information under these conditions have privacy requirements that apply to their handling of your information. When you provide personally identifiable information to MAIA, it will be accessible to some of MAIA’s third-party vendors or contractors, service providers, such as companies we retain to fulfill requests for information, answer telephone calls or provide assistance to us on specific programs or projects. In those cases, the other companies may also hav
Jobs × 🎁 You have got a free gift! Add your free gift to the cart Skip to content - reviews Open navigation menu Open search Shop New Singles Bundles By routine step Cleanse Exfoliate Mask Tone Treat Moisturise Protect By skin type Blemished skin Combination skin Dry skin Oily skin Normal skin By body part Face Body Accessories Bestsellers Knowledge Ingredients Guide Blog About Mission Sustainability Production Ingredients Story Press Diagnostic → Bestsellers Viva Maia EN Language English Deutsch Open search Open account page Open cart 0 Shop Knowledge About Diagnostic → Bestsellers Eng … ll backgrounds, identities, and experiences. If you need any adjustments to the application process, just let us know. Job openings We currently have no open positions, but we are always interested in connecting with talented individuals who share our passion for blending tradition with innovation. Please feel free to submit your resume to [email protected] , and we'll keep it on file for future opportunities. Become part of our community, secure exclusive benefits, and st
Contact - Maia Biotechnology About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu X LinkedIn Contact Us Follow a manual added link 444 West Lake Street Suite 1700 Chicago, IL 60606 Follow a manual added link (312) 416-8592 Send an E-Mail to: mailto:[email protected] [email protected] 444 W Lake St STE 1700, Chicago, IL 60606 (312) 416-8592 [email protected] Collaboration Inquiries: [email protected] I
Jobs at MaiaSpace Skip to content MaiaSpace Homepage MaiaSpace Homepage MaiaSpace Homepage MaiaSpace Homepage MaiaSpace Homepage MaiaSpace Homepage MaiaSpace Homepage MaiaSpace Homepage Join us At MaiaSpace , we’re building the next generation of European space mobility. Our ambition: to design, manufacture, and operate sustainable, reusable launch systems that combine the agility and innovation of NewSpace with the expertise, excellence, and heritage of the European space industry. We believe that space is a catalyst for improving life on Earth . Our teams are united by a shared mission — to
Jobs at MAIA | JOIN MAIA 11-50 employees Software Development We are driven by our passion for innovation! MAIA is the AI platform built for industrial companies - the places where generic AI tools break down because the data is complex, th… Read more Website LinkedIn Open positions 4 About us Mission Benefits Values Offices Open positions Department All departments Location All locations Senior Applied AI Engineer (f/m/x) Remote (Germany) Employee Software Development 75.000 € to 85.000 € / year Senior Backend Engineer Applied AI Track (m/w/d)(Leipzig) Leipzig, Germany (hybrid) Employee Engin … x) Remote Employee Software Development 75.000 € to 85.000 € / year Spontaneous Application 4 of 4 results About us We are driven by our passion for innovation! MAIA is the AI platform built for industrial companies - the places where generic AI tools break down because the data is complex, the stakes are high, and precision actually matters. We focus on the hard problems: integrating with real engineering workflows, understanding complex technical documents, and turning impl
Careers - Maia Biotechnology About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu X LinkedIn Careers MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. If you’re interested in working at MAIA, please review the current open
Maia Ventures launches $64m agrifoodtech fund You are using an outdated browser. Please upgrade your browser to improve your experience. Menu About Us Newsletter Investor Q&A Global report 2026 Insect ag Iran war Video Breaking: Italy’s Maia Ventures launches $64m agrifood fund backed by EIF and others October 14, 2025 | Jennifer Marston Agtech Biomanufacturing & biologicals Climate & sustainability Corporates FoodTech Investing Nutrition & health Startups & funding Supply chain Maia Ventures founding partners David Bassani (left) and Andrea Galassi. Image credit: Mai … ssani (left) and Andrea Galassi. Image credit: Maia Ventures Italy-based impact fund Maia Ventures has launched its first fund at €55 million ($64 million) that will support early-stage food and ag ventures addressing health, resilience, and efficiency in the food system. The fund is fully operational and has already made six investments to date. As an impact fund, Maia’s investment areas fall into three main impact buckets, say founding partners David Bassani and Andre … building more resilience into the food sector. Initial ticket sizes for the new fund range from €0.5 to 1.5 million, says Maia, which plans to back a total of 20 to 25 companies including those named above. The firm expects to make a final close of the fund “in the coming months.” ‘A good time to be deploying capital’ Maia Ventures’ limited partner (LP) base includes institutional investors the European Investment Fund (EIF) and CDP Venture Capit … dtech saw this play out in the early 2020s, when generalist investors rushed to fund alternative protein and indoor farming startups. “We realized that the way to fundraise was not to go to ‘tourists’ but to approach institutions, corporates and family offices connected to corporates in the agrifood food space,” Bassani tells AgFunderNews . “These are the people who are not subject to fads and trends. These are the guys who know the real problems … akthrough agrifoodtech innovation,” Claudia Pingue, head of tech transfer fund of CDP Venture Capital, said in a statement. “The team’s deep expertise and robust network enable them to identify high-impact deep-tech solutions at the intersection of nutraceutical, food and health, where long-term value and systemic resilience are estab
--> Private Equity List | Maia Ventures PE/VC lists Private Equity Venture Capital New PE/VC Other By Industry By Country By City By State (US) By Industry By Country By City By State (US) Table view Map view Grants, incubators and accelerators Alternative financing SME debt financing Crowdfunding & P2P Pricing New PE/VC Table view Map view AI Search More About Top PE firms 2026 Top VC firms 2026 Database stats Contacts Blog Ads & sponsorship Other PEL vs Other Services Resources PE&VC Associations PE&VC Investment process Crowdfunding primer Log In Find PE/VC funds Try for free PE … companies like Foreverland, Exolab Italia, and Biorsaf. Maia Ventures manages a fund size of €55 million, aiming to support around 25 portfolio companies. Notable investments by Maia Ventures include Foreverland - a sustainable chocolate alternative, Exolab Italia - a biotech company extracting plant-derived exosomes, and Biorsaf - a SaaS solution for food safety compliance. Other investments include Lembas, Cappellini Veg Lab, and GenoGra, showcasing their commitment to inno … ntures Funds Name Type Industry Stage Region Size AUM Launch date Maia Ventures Fund I Venture Capital (VC) Food and Beverage Foodtech Healthcare Services SaaS Software HealthTech Pre-seed Seed Europe $5-10 m $54 M October 2025 Maia Ventures Fund Venture Capital (VC) Food and Beverage Foodtech AgriTech North America Europe $0-1 m $59.5 M March 2026 Contacts Upgrade to see contacts Name Title Email Social Networks 4Zln62eSGRmp8JQs 4Zln62eSGRmp8JQs 4Zln62eSGRmp8JQs [email  … a Ventures has around $64m assets under management. When was Maia Ventures last fund created? Maia Ventures last fund was created/launched in 2026-03-29 Is Maia Ventures impact investor? Yes, Maia Ventures is impact investor. 🔥 Limited Flash Deal: 20% off Sign up before the timer runs out! Copy promocode below to Stripe checkout to get the discount for any product 12 Hours 00 Minutes 00 Seconds WELCOME Industries Biotechnology Edtech E-commerce Fintech Robotics See all Inves … stors Private Equity Venture Capital Angel investors Corporate VC Family office Fund of funds All Investors Stage Pre Seed Seed Series A Series B Late Stage (Series C+) Resources Resources PE&VC associations PE&VC investment process Crowdfunding primer Top PE firms 2026 Top VC firms 2026 How to Get Funding for a Startup AI Search Database stats C
MAIA | Project Documents You are using an outdated browser. Please click here to upgrade or change your browser. NASA Jet Propulsion Laboratory California Institute of Technology MAIA Home Science Objectives MAIA and Your Health Air Pollution Health Effects Who is Affected? Epidemiology Mission MAIA Target Areas Satellite Observatory Surface Monitoring Network Data to PM Maps Health Studies Resources Data and Applications Publications Project Documents News FAQs Science and Project Team Geographic Information Visualization Tool Skip Navigation menu and search http://w
MAIA CEO, director add about 72.7k, 75k shares | MAIA Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Gas … raise funding trial Neutral +3.3% $33M common stock offering expected to fully fund pivotal Phase 3 trial. Mar 31 Phase 2 survival data Positive +6.9% Eight NSCLC patients showed overall survival beyond two years in THIO-101. Mar 04 Underwritten equity offering Negative -1.9% $30M underwritten offering of 20M shares at $1.50 to fund trials. Pattern Detected Recent clinically focused announcements often saw negative price reactions, while strong survival data and financing cl
Maia Ventures | Portfolio, Investments & AUM | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Investors Maia Ventures Maia Ventures Milan maia.vc Overview Maia Ventures is a venture capital firm based in Milan, Italy, that invests in early-stage agrifood tech companies at the intersection of food, health, and sustainability. Year Founded 2024 Portfolio Companies 4 Website maia.vc Investments Company Date Stage Lead Rainbow Crops Jun 2026 Seed Co-investor Foreverland Mar 2026 Early Funding Lead GenoGra Feb 202
MAIA Biotechnology Expands Phase 2 Study in Romania - The Globe and Mail Home Canada Business Investing Life Opinion World Politics Personal Finance Culture Sports More More Latest in More Real Estate Drive Watchlist For You Events Find clarity in the chaos. Subscribe now and save 70% Subscribe Digital access Digital + home delivery TSX 0.37 % S&P 500 -0.05 % DOW -0.09 % NASDAQ -0.24 % Oil -3.74 % Dollar 0.05 % Gold 1.2 % tsx movers: CNQ-T -0.3 % BB-T + 10.33 % SU-T -0.87 % TRP-T -0.77 % This section contains press releases and other materials from third parties (including paid content). T … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Registry Modern Slavery Report AI Guidelines Subscribe Digital + Home Delivery Digital Access Globe2Go The New York Times Globe Email … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Registry Modern Slavery Report AI Guidelines Jump to footer navigation © Copyright 2026 The Globe and Mail Inc. All rights reserved. 3
%PDF-1.5 %���� 1 0 obj >stream x����� ���U�Q��� endstream endobj 2 0 obj >]/Intent/Perceptual/Subtype/Image/Height 247/Filter/FlateDecode/Type/XObject/Width 1428/SMask 1 0 R/Length 24941/BitsPerComponent 8>>stream x���U�:F�-L iaZ�Z�Z�Z�Z�Z�=+{嬃$+�f���VpdY� K�| �""""""""""""""""""""""""""""""""""�6 ���ooo���/����ć�B�bQ8v�ӭ� H���Ϗ������� �M�b�����������UACDDDDDDD.���������a��7ů_������s���n��ʑ2^^^�1DDDDDDDd������Ƭ�b��ǖ�~�L8����� ǖ����J�D�y�ǁ���Q������!�_~V"""""""�W.!� B&�(�p" 7b/�����rC�r�WPal�� �������H��*G�0�P�/� �C|||�{ȯ_���HՂ�Q C^��#�M���
MAIA Biotech CEO presents at Smart Diaspora 2025 | MAIA Biotechnology, Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you … ice reached $5.99 per share. The BoD and CEO failed to secure enough capital to fund the remainder of Phase 2 and Phase 3. Like Reply 1 Reaction 2 Reactions To view or add a comment, sign in More Relevant Posts Luminary Group 45,642 followers 6mo Report this post 𝗔 𝗕𝗶𝗴 𝗦𝘁𝗲𝗽 𝗙𝗼𝗿𝘄𝗮𝗿𝗱 𝗳𝗼𝗿 𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗗𝗲𝗴𝗿𝗮𝗱𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗔𝗠𝗟!!! Exciting momentum from Amphista Therapeutics Limited , as new preclinical data push its BRD9 de
Biomentorhub - We’re excited to announce Dr. Vlad Vitoc,... Facebook Log In Biomentorhub's Post Biomentorhub November 7, 2024 · Shared with Public We’re excited to announce Dr. Vlad Vitoc, Founder and CEO of MAIA Biotechnology, Inc., as a speaker at 4BiOMed US! With over 24 years in oncology pharma and biotech, Dr. Vitoc has led the development of therapies for multiple cancer types, holding key roles at Bayer, Novartis, Incyte, and more. At MAIA Biotechnology, Dr. Vitoc is pioneering THIO, an innovative anticancer agent focused on hard-to-treat cancers like Non-Small Cell Lung Cancer, wi
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
MAIA Technology Secures Strategic Investment from Molten Ventures | MAIA Technology Limited posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join … bered scale and cost savings. MAIA consistently answers to these calls with its award-winning platform. This investment empowers MAIA’s leadership to continue building an independent, focused and client-centric business. With Molten’s support, we go further: accelerate, broaden and enhance our capabilities right across the investment value chain to help firms operate with even greater clarity and efficiency. You can read the full Press release here: https://lnkd.in/eaQRd2aa M … rity investment in our business. This represents a strong endorsement of MAIA’s award-winning technology, our team, our vision and the value we continuously deliver to asset managers and hedge funds right across the Buy-Side. We are doubling down on what makes MAIA unique and momentum has never been stronger. We are building the future of investment operations. The full press release can be found here: https://lnkd.in/eaQRd2aa 5 Like Comment Share Copy LinkedIn Facebook X To … shaping these important standards. Paul Cunningham , Partner — Investment & Fund Structuring at GPCA Member firm Helios Investment Partners , serves on the IPEV Board and contributes to the development of these guidelines. #VC #PE #privatecapital #invest 10 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in PCG Advisory Group 2,112 followers 5mo Edited Report this post SKYX Platforms Announces $4 Million Strategic Investment from Philo … is post SKYX Platforms Announces $4 Million Strategic Investment from Philotimo Fund, LP, Investor in Growing Small-Cap Companies, at $2.00 Per Share in Straight Common with No Warrants https://lnkd.in/eDuatQFx 8 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Sidley Austin LLP 140,002 followers 4mo Report this post
MAIA Biotechnology Announces Year-to-Date Achievements and Highlights Recent Clinical Progress for Novel Anticancer Agent :: MAIA Biotechnology, Inc. (MAIA) About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu x LinkedIn Press Releases Investors Investors Overview News & Events Press Releases IR Calendar Email Alerts Company Info Management Team Analyst Coverage Presentations Contacts FAQ Stock Data Quote Cha … 1, 2024 with $6.4 million of this amount due to sales under the ATM facility to fund continuing clinical development. Our independent directors have shown continued support by investing almost $900,000 in our March and April 2024 private placements with other accredited investors. MAIA’s Phase 2 THIO-101 clinical trial is expected to near completion in 2024. The Company is also engaged in research and development for a portfolio of second-generation THIO-like compounds. About
Our Impact - MAIA --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> Skip to content English Español WHO WE ARE About us Organizational Information Our team FAQ OUR IMPACT Our Impact Our Programs LATEST GET INVOLVED KAQCHIKEL WHO WE ARE About us Organizational Information Our team FAQ OUR IMPACT Our Impact Our Programs LATEST GET INVOLVED KAQCHIKEL DONATE NOW DONATE NOW WHO WE ARE About us Organizational Our Team OUR IMPACT Our Impact Our Programs LATEST Girl Pioneers’ Voices MAIA’s Voices Blog GET INVOLVED DONATE Donate to MAIA Recurring Giving Program KAQ … ponse. READ MORE Awards 2023 Top-Ten finalist – World’s Best School Prize in the category of Overcoming Adversity 2021 winner – .ORG Impact Award for championing diversity, equity, and inclusion 2021 recognition – HundrED.org – Inter-American Development Bank for 21st-century skills 2020 winner – MIT SOLVE for girl and women innovators 2019 winner – Zayed Sustainability Prize for innovative, impactful, & sustainable solutions MORE
EX-99.2 Exhibit 99.2 Vlad Vitoc, MD, MBA Chief Executive Officer 444 West Lake Street, Suite 1700 - Chicago, IL 60606 (312) 416-8592 [email protected] (215) 971-5488 maiabiotech.com Telomere Targeting Immunotherapies for Cancer MAIA is an immuno-oncology company focused on the development and commercialization of first-in-class drugs intended to meaningfully improve and extend the lives of people with hard-to-treat cancers. We are exploring new science for cancer therapy utilizing a novel dual mechanism of action: telomere targeting and immunogenicity. Our lead program is THIO, a first-in
$4.6 Million Public Offering of MAIA Biotechnology, Inc. | Loeb & Loeb LLP Skip to content EN 中文 People Insights Services About Close People Insights Services About News & Events Locations Inclusion Pro Bono Alumni Careers Contact Us Industries Advertising & Media Entertainment, Music & Sports Financial Services Life Sciences Nonprofits & Tax-Exempt Organizations Private Client Real Estate Technology Practices Capital Markets, Corporate & Finance Employment & Labor Intellectual Property Investigations & Compliance Litigation Privacy, Security & Data Innovations Restructuring & Bankruptcy T … m.nameError}} Email {{emailForm.emailError}} Message {{emailForm.messageError}} Submit Email has been submitted successfully. Thanks! Error sending the email. Please try again later. vCard Download By clicking on the Submit button below, you are downloading the Loeb contact's vCard Submit $4.6 Million Public Offering of MAIA Biotechnology, Inc. Represented MAIA Biotechnology, Inc. a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, in a
MAIA Biotechnology, Inc. Raises $8.0 Million Financing to Advance Pipeline of Targeted Immuno-Oncology Studies :: MAIA Biotechnology, Inc. (MAIA) About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu x LinkedIn Press Releases Investors Investors Overview News & Events Press Releases IR Calendar Email Alerts Company Info Management Team Analyst Coverage Presentations Contacts FAQ Stock Data Quote Charts Histori
How Maia Bittner became a key PM at Chime | Amber Illig posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s
Maia McLaren – Textile Design – School of Design – Showcase 2026 Search Search The Glasgow School of Art GSA Showcase 2026 Visitor Information Prizes Features --> Mackintosh School of Architecture → MArch by Conversion MSA Stage 3 MSA Stage 4 MSA Stage 5 004 .............................................................................................................................. departments 062 .............................................................................................................................. students Location ................................................
Funding the Fungi Future: Joyful Ventures' Strategic Stake in Maia Farms About Focus Team ESG Blog Portfolio About Why Focus imagine Team Values ESG Blog Portfolio Funding the Fungi Future: Joyful Ventures' Strategic Stake in Maia Farms From Space Challenges to Earthly Solutions: Maia Farms' Award-Winning Journey By Milo Runkle Maia Farms mycelium-based protein, CanPro™, has 5.5X the iron of beef with a 99.6% digestibility score. Maia Farms , recently crowned grand prize winner of the prestigious Deep Space Food Challenge, has just closed $2.3 million in an oversubscribed pre-se … gnition in Deep Space Food Challenge In April, Maia Farms was crowned the grand prize winner of the Deep Space Food Challenge hosted by NASA and the Canadian Space Agency. This accolade highlights Maia Farms' innovative approach and capability in developing sustainable food solutions that could potentially support long-duration space missions and enhance food security on Earth. Gavin Schneider, CEO of Maia Farms, shared his excitement about the recent achievements and fu … 2023 Joyful Ventures Unveils: The Media Buzz Around Our New Sustainable Protein Fund June 14, 2023 Upside Foods Receives USDA Approval for Cultivated Meat Label April 5, 2023 The Unstoppable Rise of Dairy-Free Milk: A 36 Percent Growth in 3 Years and Counting March 27, 2023 Cultivated Meat Takes Another Step Toward Entering the Market March 10, 2023 Report predicts 60% of the world's meat will come from vegan and cultivated sources by 2040 February 9, 2023 Plant-Based Al
About Us - Maia Biotechnology About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu X LinkedIn About MAIA Our mission is to research, develop, and deliver innovative medicines to improve and extend the lives of people with cancer. MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Effect of a driving pressure-limiting strategy for patients with acute respiratory distress syndrome secondary to community-acquired pneumonia: the STAMINA randomised clinical trial Effect of a driving pressure-limiting strategy for patients with acute respiratory distress syndrome secondary to community-acquired pneumonia: the STAMINA randomised clinical trial Br J Anaesth . 2025 Mar;134(3):693-702. doi: 10.1016/j.bja.2024.10.012. Epub 2024 Nov 26. Authors Israel Silva Maia 1 , Alexandre Biasi Cavalcanti 2 , Lucas Tramujas 3 , Viviane Cordeiro Veiga &nbs
S-1 1 maia-s1.htm S-1 maia-s1.htm As filed with the U.S. Securities and Exchange Commission on April 8, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1495913 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification No.) … ur regulatory strategy includes a planned filing of an Investigational New Drug application (IND) with the U.S. FDA. This would allow U.S. sites to participate in the THIO-101 NSCLC trial. The human safety data generated in the first part of 2022 in Australia and Europe would constitute the basis of the IND application. Although we plan to rely solely on the safety and efficacy data we generate in our own clinical trials in support of our planned NDA filing, and do not plan t … ss for the clinical sites for our Phase 2 study in Australia and Europe and our application to start the Phase 2 study in Australia has been approved. We also plan to submit a similar application in the Second Quarter 2022, to conduct the same Phase 2 study in Europe. 3 Our Second Generation Target Candidates Our THIO program drives our development pipeline of second-generation telomere targeting agents. We have initiated an early-stage research an … adoption of certain accounting standards until those standards would otherwise apply to private companies. We intend to take advantage of the benefits of this extended transition period. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the completion of this offering, (b) in which we have total annual gross revenue of at least $1.07 billion, or (c) in which we are deemed to be a large ac … ceeds from this offering, along with our existing cash and cash equivalents, to fund the planned trials of THIO, pre-clinical development of second-generation of telomere targeting compounds and our other research and development activities, as well as for working capital and other general corporate purposes. See “Use of Proceeds” in
MAIA Biotechnology, Inc. (MAIA) About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu x LinkedIn Investor Relations Investors Investors Overview News & Events Press Releases IR Calendar Email Alerts Company Info Management Team Analyst Coverage Presentations Contacts FAQ Stock Data Quote Charts Historical Data SEC Filings All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Board of D
Acquisition Lab - Maia Swisdak, Amudha Krishnan and Elizabeth Swanson / Marshmallo-WH Queen | Department of Linguistics Skip to main content Skip to main content Apply Give Trigger Search Search this Site Go Menu Trigger Menu Close Search this Site Go Primary Header Navigation ARHU Home Home About Academic Programs Undergraduate Bachelor of Arts in Linguistics Linguistics Minor Curriculum Honors Programs Baggett Summer Scholarships FAQs Graduate Ph.D. Program Current Ph.D. Students Funding FAQs Baggett Post-Bac Fellowship Baggett Programs Research Syntax Semantics Phonology Language Acquisitio … s Research Resources & Facilities Our Community Secondary Footer Navigation Apply Give People Events News Contact Current Students Prospective Students Our Community Today's View Follow Us © 2026 University of Maryland Log In Privacy Policy Web Accessibility
MAIA Biotechnology Announces Open Market Purchases by CEO and Directors :: MAIA Biotechnology, Inc. (MAIA) About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu x LinkedIn Press Releases Investors Investors Overview News & Events Press Releases IR Calendar Email Alerts Company Info Management Team Analyst Coverage Presentations Contacts FAQ Stock Data Quote Charts Historical Data SEC Filings All SEC Filings An
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.
MAIA | Data and Applications You are using an outdated browser. Please click here to upgrade or change your browser. NASA Jet Propulsion Laboratory California Institute of Technology MAIA Home Science Objectives MAIA and Your Health Air Pollution Health Effects Who is Affected? Epidemiology Mission MAIA Target Areas Satellite Observatory Surface Monitoring Network Data to PM Maps Health Studies Resources Data and Applications Publications Project Documents News FAQs Science and Project Team Geographic Information Visualization Tool Skip Navigation menu and search http
CHG-MERIDIAN acquires asset portfolio of Australian company Maia Financial Pty Limited Accessibility Statement Skip Navigation Resources Data Privacy Contact Us Send a Release News Products Contact General Inquiries Request a Demo Partnerships Media Inquiries Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only All Multimedia All Multimedia All Photos … ervices All New Releases Platform Do not sell or share my personal information: Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact Cision Products About My Services All News Releases Platform [email protected] Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookie Settings Accessibility Copyright © 2026 Cision US Inc. --> -->
Home - Maia Biotechnology About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu X LinkedIn Telomere Targeting Immunotherapies for Cancer Link to: About Us About Us Link to: Pipeline Our Pipeline Follow a manual added link Investors Pipeline products are under clinical investigation and have not yet been proven to be safe and effective. © Copyright 2026 - MAIA Biotechnology, Inc. 312.416.8592 &
MAIA | Home Page You are using an outdated browser. Please click here to upgrade or change your browser. NASA Jet Propulsion Laboratory California Institute of Technology MAIA Home Science Objectives MAIA and Your Health Air Pollution Health Effects Who is Affected? Epidemiology Mission MAIA Target Areas Satellite Observatory Surface Monitoring Network Data to PM Maps Health Studies Resources Data and Applications Publications Project Documents News FAQs Science and Project Team Geographic Information Visualization Tool Skip Navigation menu and search http://www.nasa.
MAIA Biotechnology Announces Open Market Purchases by CEO --> Accessibility: Skip TopNav MAIA Biotechnology Announces Open Market Purchases by CEO and Director June 02, 2026 09:45 ET | Source: MAIA Biotechnology, Inc. MAIA Biotechnology, Inc. CHICAGO, June 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that its founder and CEO Vlad Vitoc, M.D. and Director Stan V. Smith, Ph.D. have increased their ownership positions
MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy :: MAIA Biotechnology, Inc. (MAIA) About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu x LinkedIn Press Releases Investors Investors Overview News & Events Press Releases IR Calendar Email Alerts Company Info Management Team Analyst Coverage Presentations Contacts FAQ Stock Data Quote Charts Historical … pies for cancer, today announced that the European Patent Office has decided to grant a patent broadly covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer therapy and methods of using ateganosine (THIO) alone or before administration of checkpoint inhibitors (CPIs). The patent, titled “Mercaptopurine Ribonucleoside Analogues for Altering Telomerase Mediated Telomere,” was invented by MAIA’s Chief Scientific Officer Sergei M. Gryaznov, PhD and
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells CHICAGO – August 13, 2025 – MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the European Patent Office has decided to grant a patent bro
MAIA Biotechnology, Inc. (Form: 8-K, Received: 11/20/2025 09:00:52) false 0001878313 0001878313 2025-11-20 2025-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   Current Report   Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): November 20, 2025   MAIA Biotechnology, Inc. (Exact name of registrant as specified in its charter)   Delaware   001-41455   83-1495913 (State or
MAIA Biotechnology sets 2026 virtual annual meeting | MAIA Proxy Statement --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks … ,747 votes. Stockholders will elect two Class I directors and vote on ratifying Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026. The proxy statement also details board structure, committee membership, executive compensation, related-party private placements involving directors and a 5% stockholder, and the company’s equity incentive plans and governance policies. Positive None. Negative None. Key Figures Shares outstan … nt to solicit proxies" independent registered public accounting firm financial "Proposal 2 Ratification of the Appointment of Grant Thornton LLP as Our Independent Registered Public Accounting Firm" An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certifica … gei M. Gryaznov Key Proposals Election of two Class I directors Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google Add on Google Not now Proxy Statements (DEF 14A): Pay, Votes, and Board Changes → Accepted by SEC EDGAR 04/07/2026 - 09:02 AM Learn about SEC filing dates ⛶ Fullscreen … Its Charter)       Payment of Filing Fee (Check all boxes that apply): ☒     No fee required.   ☐     Fee paid previously with preliminary materials.   ☐     Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. &
Board of Directors - Maia Biotechnology About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu X LinkedIn Board of Directors Vlad Vitoc, MD, MBA Chairman Steven M. Chaouki Ramiro Guerrero, JD, LL.M. Louie Ngar Yee Cristian Luput Stan V. Smith, PhD Jean-Manassé Théagenè, MSc MBA Vlad Vitoc, MD, MBA Chairman Dr. Vitoc is our Chairman of Board, Chief Executive Officer, and President. Dr. Vitoc has a broad array of exp
Scientific Advisors - Maia Biotechnology About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu X LinkedIn Scientific Advisors David M. Ashley MBBS (Hon), FRACP, PhD Tudor Ciuleanu MD, PhD Z. Gunnur Dikmen MD, PhD Jerry W. Shay PhD Adam Yopp PhD Remus Vezan MD, PhD Saadettin Kiliçkap M.D, M.Sc David J. Pinato MD, MRCP (UK) FRCPath, MRes, PhD Claudia A.M. Fulgenzi MD David M. Ashley MBBS (Hon), FRACP, PhD David M. A … s in translational research and leadership. As evident from his publication and grant support record, his primary academic focus has been on neurologic tumors, the development of innovative therapies and approaches to care. These efforts have included basic and translational laboratory research. Dr. Ashley’s experience includes moving laboratory findings in brain tumor immunology and epigenetics into early phase clinical trials. He has expertise in immuno-oncology, having dev … graduated from Ankara University Medical Faculty and subsequently completed her residency and received her PhD from Hacettepe University Medical Faculty, Department of Medical Biochemistry. She completed her doctoral research at the University of Texas Southwestern Medical Center, Department of Cell Biology in the Shay-Wright Lab. Her research has been focused on the discovery of novel molecules targeting telomeres and telomerase, mainly working on GRN163L (Imetelstat®) and 6 … Science program in 2003 and received the Hacettepe University-Science Incentive Award in 2010. Jerry W. Shay PhD Jerry W. Shay, PhD, Professor and Vice Chairman of the Department of Cell Biology, University of Texas Southwestern Medical Center. Dr. Shay is one of the world leaders in the study of telomeres and telomerase. Professor Shay is the scientific co-founder of the research supporting THIO and is an integral advisor to the program. He has been a consultant and a member … thwestern having received the University of Texas Regent’s Outstanding Teaching Award, and the Minnie Steven Piper Foundation Professor Award. Dr. Shay was also awarded the Eunice Kennedy Shriver NIH Alliance Pioneer Award. Dr. Shay received his PhD from the University of Kansas and completed his postdoctoral training at the University of Colorad
Interview with the Chairman and CEO: MAIA Biotechnology Inc. (NYSEAMERICAN:MAIA) - The Wall Street Transcript Toggle navigation Home Experts Reports Products News About Us Series General Investing Financial Services Consumer Industry & Services Natural Resources Healthcare Technology Contact Us Login New Login New Reg --> Healthcare >> CEO Interviews >> April 29, 2025 Interview with the Chairman and CEO: MAIA Biotechnology Inc. (NYSEAMERICAN:MAIA) Vlad Vitoc, M.D., is Chairman of Board, Chief Executive Officer, and President of MAIA Biotechnology Inc. Dr. Vitoc has a broad arr
Teatrul National Cluj-Napoca About us What's on Tickets Productions Events FESTIVAL Sponsors and partners Virtual tour Pagina mobile RO EN Poster gallery Photo gallery Video gallery Premii și distincții Reviews archive Back Maia Banciu   Maia Banciu - A Short Biography      Maia's career has encompassed non-profit, corporate and free-lance work with prestigious Romanian-based international organizations: Connex/Vodafone, PHARE-VET, The Soros Foundation for an Open Society, Habitat for Humanity, where she gained hands-on experience in PR, CSR, brand communicatio … conducting wine tastings and wine courses. In 2015, she gained the WSET Level 2 Award in Wines & Spirits. In 2003, she dedicated her efforts to the creation of a new party (URR - The Union for the Reconstruction of Romania) with a clear anti-corruption agenda. Maia is a passionate advocate of Corporate Social Responsibility and civic implication. She was invited to speak on these topics on a number of occasions and events hosted by AIESEC - " Payroll Giving ", OSUB - "Cul
MAIA Biotechnology, Inc. Announces Formation of Scientific Advisory Board :: MAIA Biotechnology, Inc. (MAIA) About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu x LinkedIn Press Releases Investors Investors Overview News & Events Press Releases IR Calendar Email Alerts Company Info Management Team Analyst Coverage Presentations Contacts FAQ Stock Data Quote Charts Historical Data SEC Filings All SEC Filings … s in translational research and leadership. As evident from his publication and grant support record, his primary academic focus has been on neurologic tumors, the development of innovative therapies and approaches to care. These efforts have included basic and translational laboratory research. Dr. Ashley’s experience includes moving laboratory findings in brain tumor immunology and epigenetics into early phase clinical trials. He has expertise in immuno-oncology, having dev … graduated from Ankara University Medical Faculty and subsequently completed her residency and received her PhD from Hacettepe University Medical Faculty, Department of Medical Biochemistry. She completed her doctoral research at the University of Texas Southwestern Medical Center, Department of Cell Biology in the Shay-Wright Lab. Her research has been focused on the discovery of novel molecules targeting telomeres and telomerase, mainly working on GRN163L (Imetelstat ® ) and … Science program in 2003 and received the Hacettepe University-Science Incentive Award in 2010. Thomas F. Gajewski, MD, PhD , AbbVie Foundation Professor of Pathology, Professor of Ben May Department of Cancer Research, Professor of Medicine and Immunology Expert, University of Chicago. Dr. Gajewski is one of the key pioneers in cancer immunotherapies and has been a key investigator on phase 1, 2 and phase 3 trials in Melanoma (with Keytruda ® , Opdivo ® , etc.). Dr. Gajewski … ie Foundation Professor for Cancer Immunotherapy, received the William B. Coley Award for contributions to the field of cancer immunology, the ESMO award in Immuno-oncology, and was inducted into the American Association of Physicians. Dr. Gajewski has published more than 220 manuscripts and 20 book chapters in these areas and has presented data
2023 – Page 219 – 1stOncology™: Cancer Intelligence Service 1stOncology™: Cancer Intelligence Service 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Skip to content 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers , signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology! Access Free Conference Whitepapers! Register for our Free Newsletter! Schedule Your Free Demo! Search for: Search … ancer therapies. THIO-101 Phase 2 Clinical Trial U.S. FDA Clearance of THIO IND Application: The U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application enabling THIO to be evaluated in the U.S. as part of THIO-101, the Company’s ongoing global phase 2 clinical study in patients with advanced non-small cell lung cancer (NSCLC). THIO is being tested in sequential combination with a checkpoint inhibitor (CPI) to evaluate anti-tumor ac … om world-class investors including Morningside and awarded $10M in non-dilutive grant funding, Participated in the Cancer Lethality Lead Collaboration, which was awarded $10M from the Prostate Cancer Foundation’s TACTICAL Awards program, in collaboration with the Peter MacCallum Cancer Centre, Uniklinik Essen, University of California Los Angeles, and University of California San Francisco. Built a 25-person world-class team across Australia and the United States and se … -Bombesin is a highly targeted pan-cancer radiopharmaceutical with broad cancer application. It targets the gastrin-releasing peptide receptor (GRPr) present on cells of a range of cancers, including but not limited to prostate, breast and ovarian cancers. GRPr is found in up to 100% of prostate cancers, including prostate cancers that don’t express PSMA (PSMA-negative)[2-6]. The product utilises Clarity’s proprietary sarcophagine (SAR) technology that securely ho
Business Wire: MAIA launches its debut project in Bangalore – Pelican Grove | MAIA Estates Business Wire: MAIA launches its debut project in Bangalore – Pelican Grove - MAIA Estates --> --> --> --> About Us Developments Services Bespoke Services Maia Life Get Connected Contact Us About Us Services + Maia Life Bespoke Services Developments Maia Impact In The News Blogs Contact Us Instagram Linkedin Business Wire: MAIA launches its debut project in Bangalore – Pelican Grove Bengaluru, Karnataka, India: Founded in 2016 by its CEO, Mr. Mayank Ruia , MAIA Estates LLP focuses on developing the highe
Datamatics acquires MAIA Business Intelligence | Careers | Press Releases | Events | Investors | Contact Us Technologies Datamatics.AI Enterprise Platforms Salesforce Microsoft Google Amazon Web Services OutSystems Digital Transformation Artificial Intelligence Data & Analytics Cloud Applications Hyper-Automation Product Engineering CRM Enterprise Content Management Professional Services Digital Assurance Managed Services Testing Automatic Fare Collect … cess Outsourcing (BPO) solutions provider, has completed its acquisition of the award winning 1KEYsuite of BI solutions from MAIA Intelligence. “To meet our growth plans and provide our enterprise customers solutions to help them derive actionable insights for optimized business outcomes, we have decided to acquire 1KEY suite of products developed by MAIA Intelligence,” said Rahul Kanodia - Vice Chairman & CEO, DGSL. 1KEY provides on-line as well as off-line BI, along wit
Co... - Vision Therapy Philippines at Vision Science Institute Facebook Log In Vision Therapy Philippines at Vision Science Institute's Post Vision Therapy Philippines at Vision Science Institute March 5, 2021 · Shared with Public Congratulations to our very own Dr. Maia Uy for being chosen to be a poster presenter in the 50th Annual Conference of the College of Optometrists in Vision Development (COVD) - USA. Along with the world experts in Behavioral & Developmental Optometry. Your Vision Therapy Philippines Family is so proud of you! Calling all Optometrists to register now. www.co
MAIA CSO buys 2,000 shares in open market | MAIA Insider Trading --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Gas
CHG-MERIDIAN acquires asset portfolio of Australian company Maia Financial Pty Limited Company Solutions Sustainability Career Media Center Search EN | DE ENGLISH GERMAN Global Site Australia Austria Belgium Brazil Canada Czechia Denmark Finland France Germany Italy Mexico Netherlands New Zealand Norway Poland Singapore Slovakia Spain Sweden Switzerland United Kingdom United States tesma login Contact Us Company Solutions Sustainability Career Media Center Global Site | EN tesma login Contact Us Asset Select Language English German Global Site Australia Austria Belgium Brazil Canada Czechia De
MAIA Biotechnology to Present at AACR Annual Meeting 2023 :: MAIA Biotechnology, Inc. (MAIA) About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu x LinkedIn Press Releases Investors Investors Overview News & Events Press Releases IR Calendar Email Alerts Company Info Management Team Analyst Coverage Presentations Contacts FAQ Stock Data Quote Charts Historical Data SEC Filings All SEC Filings Annual Reports Q
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor :: MAIA Biotechnology, Inc. (MAIA) About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu x LinkedIn Press Releases Investors Investors Overview News & Events Press Releases IR Calendar Email Alerts Company Info Management Team Analyst Coverage Presentations Contacts FAQ Stock Data Quote Charts Historical Data SE
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 14A (Rule 14a-101)   INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION   Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant   ☐ Check the appropriate box:   ☐ Preliminary Proxy Statement   ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement   ☐ Definitive … strant as Specified In Its Charter) Payment of Filing Fee (Check all boxes that apply): ☒ ​ ​ No fee required.   ☐ ​ ​ Fee paid previously with preliminary materials.   ☐ ​ ​ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. MAIA Biotechnology, Inc. 444 West Lake Street, Suite 1700 Chicago, IL 60606 NOTICE OF INTENT TO CONVENE IN VIRTUAL MEETING FORMAT THE A … uction on how to access the virtual Annual Meeting and how to listen, vote, and submit questions from home or any remote location with Internet connectivity. At the Annual Meeting, we will consider and vote upon the following items: 1 To elect Louie Ngar Yee and Steven Chaouki to our board of directors as Class I directors of the Company; 2 To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the year ending December … he Annual Meeting, please complete, date, sign and return the enclosed proxy or submit your proxy through the internet or by telephone as promptly as possible in order to ensure your representation at the Annual Meeting. If you have requested physical materials to be mailed to you, then a return envelope (which is postage prepaid if mailed in the United States) is enclosed for your convenience if you choose to submit your proxy by mail. Even if you have voted by proxy, you ma … ven Chaouki to our board of directors as Class I directors of the Company (Proposal 1); 2 To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the year ending December 31, 2023 (Proposal 2); 3. To approve an amendment to the MAIA Biotechnology, Inc. 2021 Equity Incentive Plan (the R
%PDF-1.4 %���� 1 0 obj > endobj 7 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 5 0 obj > endobj 6 0 obj > endobj 8 0 obj > endobj 9 0 obj > endobj 10 0 obj > endobj 11 0 obj > endobj 12 0 obj > endobj 13 0 obj > endobj 14 0 obj > endobj 15 0 obj > endobj 16 0 obj > endobj 17 0 obj > endobj 18 0 obj > endobj 19 0 obj > endobj 20 0 obj > endobj 21 0 obj > endobj 22 0 obj > endobj 23 0 obj > endobj 24 0 obj > endobj 25 0 obj > endobj 26 0 obj > endobj 27 0 obj > endobj 28 0 obj > endobj 29 0 obj > endobj 30 0 obj > endobj 31 0 obj > endobj 32 0 obj > endobj 33 0 obj > endobj … ���G�Hw����7��+ C[ⱘ$�4�c�,������d�Q=��̈P���B� �d� �gf J� ���w/o�E��K=1_b�Rfp)�>�b8��u��!o>���{�u0E�2�o,���P�FG"�����K��:E��Oh �v��g�Y� �3 .��SӞyϢ� ?[Y_@V�Һ �sº�4쁺g�3��L{�y=� �-0���θu�#��Eo�a��X���4P�bwa���,�`'�i��Ț�� l����ȥV�4v���{ѕ1�Y*�-U*�M� ;���f[g���p�xkْÏ���W���c�������@���1��J2(�a �l�H��u�eS2���bO=s��dXMss��dxM2�~��×�/�%� ���L����m�N�S�h���b2}��r�� �x��=�)pR�E�w��s Ɍ��u�Ɏ���sn_ٴI ��Ӄ��A� ;݅��ѱ9l��o ���;ђQW�.�g��y
Careers - Maia Biotechnology About About Us Management Board of Directors Scientific Advisors Advisors Careers Programs Pipeline Ateganosine (THIO) Program Second-Generation Programs Publications Partners Investors Policies and Position Statements Contact Menu Menu X LinkedIn Careers MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. If you’re interested in working at MAIA, please review the current open